Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | LATS1 | O95835 | 5/20 | 0.36 |
| ▸ | LATS2 | Q9NRM7 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | KDM4B | O94953 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | VCP | P55072 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19160414 | 0.98 | KDM4C (0.41) | KDM4CEGFRLATS1LATS2KCNH2 | |
| SCHEMBL19160607 | 0.88 | EGFR (0.37) | EGFRKCNH2ATMNPC1RAB9A | |
| SCHEMBL19160485 | 0.87 | DYRK1A (0.35) | KDM4CEGFRLATS1KDM4AKDM4B | |
| SCHEMBL19160659 | 0.87 | KCNH2 (0.36) | KDM4CEGFRKCNH2ATMNPC1 | |
| SCHEMBL19160405 | 0.80 | NPC1 (0.48) | NPC1RAB9A | |
| SCHEMBL20911311 | 0.79 | LATS1 (0.38) | KDM4CLATS1LATS2 | |
| SCHEMBL19160452 | 0.75 | CCNC (0.36) | EGFR | |
| SCHEMBL19160392 | 0.75 | EGFR (0.36) | EGFRPDGFRBPDGFRA | |
| SCHEMBL6833209 | 0.74 | EGFR (0.42) | KDM4CEGFRLATS1LATS2KDM4A | |
| SCHEMBL19160440 | 0.74 | EGFR (0.35) | EGFRPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230558-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-01-25 | — | — | US | disclosed |
| US-11008341-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-05-18 | — | — | US | disclosed |
| US-10865214-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | The Trustees of Columbia University in they City of New York (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200216469-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | UNIV COLUMBIA (US) | 2020-07-09 | — | — | US | disclosed |
| US-10626124-B2 | — | — | 2020-04-21 | — | — | US | disclosed |
| US-20190112317-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | NY STATE PSYCHIATRIC INSTITUTE | 2019-04-18 | — | — | US | disclosed |
| US-20170210759-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2017-07-27 | — | — | US | disclosed |
| US-20170210759-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112317-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | MAPT, SQSTM1, ATG7 | KDM4C 3959/4885EGFR 4262/4885LATS1 1201/4885 |
| US-11008341-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | MAPT, SQSTM1, ATG7 | KDM4C 3959/4885EGFR 4262/4885LATS1 1201/4885 |
| US-10626124-B2 | — | MAPT, SQSTM1, TFEB | KDM4C 3232/4885EGFR 3983/4885LATS1 1086/4885 |
| US-11230558-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | MAPT, SQSTM1, ATG7 | KDM4C 3959/4885EGFR 4262/4885LATS1 1201/4885 |
| US-10865214-B2 | Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies | MAPT, SQSTM1, ATG7 | KDM4C 3959/4885EGFR 4262/4885LATS1 1201/4885 |
| US-20200216469-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | MAPT, SQSTM1, ATG7 | KDM4C 3959/4885EGFR 4262/4885LATS1 1201/4885 |
| US-20170210759-A1 | ACTIVATORS OF AUTOPHAGIC FLUX AND PHOSPHOLIPASE D AND CLEARANCE OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES | MAPT, SQSTM1, ATG7 | KDM4C 3959/4885EGFR 4262/4885LATS1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.